C-Ray Therapeutics is dedicated to delivering end-to-end solutions for innovative radiopharmaceuticals to clients around the world. Our services span process development, quality research, preclinical evaluation, IND Enabling, clinical supply, and commercial scale cGMP production, all backed by a reliable, robust logistics network. As of 2024, we have raised over USD 187 million in total funding.
C-Ray Therapeutics has successfully delivered and continues to operate 50 CRDMO projects, including 35 preclinical and molecular imaging CRO projects and 15 CDMO projects. Among these, 6 have entered the IND and IND-enabling stages, 7 have advanced to investigator-initiated trials (IITs), and 2 have entered the clinical supply stage, with 1 of them successfully progressing to a Phase III clinical study. The company has achieved comprehensive coverage of all critical links across the entire radiopharmaceutical R&D and manufacturing chain.
As a dedicated CRDMO partner in radiopharmaceuticals, one of our core strengths is a stable, diversified supply of radionuclides. We are actively developing high-quality domestic sources while playing a leading role in integrating and fortifying the global supply chain—most notably securing access to challenging isotopes such as Ac-225. To date, we have supported the development of 14 Ac-225–labeled projects.
